[go: up one dir, main page]

WO2012065059A3 - Treatment of atherosclerosis with bmp-alk3 antagonists - Google Patents

Treatment of atherosclerosis with bmp-alk3 antagonists Download PDF

Info

Publication number
WO2012065059A3
WO2012065059A3 PCT/US2011/060365 US2011060365W WO2012065059A3 WO 2012065059 A3 WO2012065059 A3 WO 2012065059A3 US 2011060365 W US2011060365 W US 2011060365W WO 2012065059 A3 WO2012065059 A3 WO 2012065059A3
Authority
WO
WIPO (PCT)
Prior art keywords
atherosclerosis
treatment
bmp
alk3
alk3 antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/060365
Other languages
French (fr)
Other versions
WO2012065059A2 (en
Inventor
Paul B. Yu
Matthias Derwall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of WO2012065059A2 publication Critical patent/WO2012065059A2/en
Publication of WO2012065059A3 publication Critical patent/WO2012065059A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Embodiments of the invention provide methods and compositions comprising an ALK3 antagonist, an ALK3-Fc and/or other functional variants thereof for the prevention and/or treatment of atherosclerosis, and its associated vascular calcification and thrombosis.
PCT/US2011/060365 2010-11-12 2011-11-11 Treatment of atherosclerosis with bmp-alk3 antagonists Ceased WO2012065059A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41316510P 2010-11-12 2010-11-12
US61/413,165 2010-11-12

Publications (2)

Publication Number Publication Date
WO2012065059A2 WO2012065059A2 (en) 2012-05-18
WO2012065059A3 true WO2012065059A3 (en) 2012-12-13

Family

ID=46051581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/060365 Ceased WO2012065059A2 (en) 2010-11-12 2011-11-11 Treatment of atherosclerosis with bmp-alk3 antagonists

Country Status (1)

Country Link
WO (1) WO2012065059A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7512272B2 (en) 2018-10-23 2024-07-08 ケロス セラピューティクス インコーポレイテッド ALK2 antibodies and methods of use thereof
EP3875117A4 (en) 2018-10-31 2022-11-09 Senju Pharmaceutical Co., Ltd. INHIBITOR OF RETINAL GANGLIONE CELL DEATH
WO2021222875A1 (en) 2020-04-30 2021-11-04 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
US20250282877A1 (en) * 2021-05-11 2025-09-11 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102603A1 (en) * 1996-02-16 2002-08-01 Dean A. Falb Compositions and methods for the treatment and diagnosis of cardiovascular disease
US20060223753A1 (en) * 2005-04-05 2006-10-05 Glass David J IGF-I and IGF-2 chimeric polypeptides and therapeutic uses thereof
US20060228332A1 (en) * 2004-06-28 2006-10-12 Merck Patent Gmbh Assembly and folding of Fc-interferon-beta fusion proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102603A1 (en) * 1996-02-16 2002-08-01 Dean A. Falb Compositions and methods for the treatment and diagnosis of cardiovascular disease
US20060228332A1 (en) * 2004-06-28 2006-10-12 Merck Patent Gmbh Assembly and folding of Fc-interferon-beta fusion proteins
US20060223753A1 (en) * 2005-04-05 2006-10-05 Glass David J IGF-I and IGF-2 chimeric polypeptides and therapeutic uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SORESCU, G. ET AL.: "Bone Morphogenic Protein 4 Produced in Endothelial Cells by Oscillatory Shear Stress Stimulates an Inflammatory", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 3, 2003, pages 31128 - 31135 *

Also Published As

Publication number Publication date
WO2012065059A2 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
MX346423B (en) Multifunctional zwitterionic polymer conjugates.
WO2011031896A3 (en) Pi3 kinase inhibitors and uses thereof
WO2011130222A3 (en) Compositions and methods comprising variant proteases
WO2011072099A3 (en) Compositions and methods comprising protease variants
HK1209785A1 (en) Compositions and methods comprising a lipolytic enzyme variant
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
PH12012501755A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
IN2012DN00572A (en)
WO2011146155A3 (en) Organo-metallic frameworks derived from carbenophilic metals and method of making same
WO2010062396A3 (en) Virus like particle compositions and methods of use
WO2011053825A3 (en) Compositions and methods for the treatment or prevention of mitochondrial diseases
WO2012088525A3 (en) Methods for treating copd
WO2014078268A3 (en) Anti-hemagglutinin antibodies and methods of use
WO2011060066A9 (en) Methods of treating or preventing stent thrombosis
WO2012073047A3 (en) Compositions and methods
EP2575855A4 (en) Methods for treating or preventing vascular graft failure
WO2012158672A3 (en) Compounds for use in treatment of mucositis
PH12013501904A1 (en) Pyridopyrazine derivatives and their use
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
WO2012065059A3 (en) Treatment of atherosclerosis with bmp-alk3 antagonists
WO2012009447A3 (en) THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
WO2012017321A3 (en) Treatment for dyslipidemia
WO2012018932A3 (en) Compounds and compositions for mitigating tissue damage and lethality
MX2010007669A (en) Methods for inhibiting angiogenesis using egfl8 antagonists.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11840017

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11840017

Country of ref document: EP

Kind code of ref document: A2